Intellia Therapeutics Investor Presentation — September 2022

Document content

Intellia is Leading the

Genome Editing Revolution

Bill, living with transthyretin amyloidosis, and his wife, Maura2

Intellia Therapeutics’ Legal Disclaimer

This presentation contains “forward -looking statements” ofIntellia Therapeutics, Inc.(“Intellia”, “we” or“our”) within themeaning ofthePrivate Securities Litigation Reform Act

of1995 .These forward- looking statements include, butarenotlimited to,express orimplied statements regarding Intellia’s beliefs andexpectations regarding :itsability tobuild

aworld -class genome editing toolbox todevelop anunsurpassed genome editing pipeline; thesafety, efficacy andadvancement ofourclinical programs forNTLA -2001 forthe

treatment oftransthyretin amyloidosis andNTLA -2002 forthetreatment ofhereditary angioedema (“HAE”) pursuant toitsclinical trialapplications (“CTA”) andinvestigational

new drug (“IND”) submissions, including theexpected timing ofdata releases, regulatory filings, andtheinitiation andcompletion ofclinical trials ;itsability tosuccessfully pivot

toanallogeneic version ofNTLA -5001 andtoadvance thisprogram, including theexpected timing ofdata releases andregulatory filings ;itsability toconsistently deliver high-

quality, readily available andpersistent allogeneic cellproducts ;theadvancement ofitsdevelopment candidates including NTLA -3001 forthetreatment ofalpha- 1antitrypsin

deficiency (“AATD”) -associated lung disease, NTLA -2003 forAATD -associated liver disease, andNTLA -6001 forCD30+ lymphomas ;theability togenerate data toinitiate

clinical trials andthetiming ofCTA andINDsubmissions ;theadvancement, expansion andacceleration ofitsCRISPR/Cas 9technology andrelated technologies, including

DNA writing, base editing, manufacturing anddelivery technologies, toadvance anddevelop additional candidates andtreatments ;theability tomaintain andexpand our

related intellectual property portfolio, andavoid oracquire rights tovalid intellectual property ofthird parties ;theability todemonstrate ourplatform’s modularity andreplicate or

apply results achieved inpreclinical studies, including those inourNTLA -2001, NTLA -2002, NTLA -5001, NTLA -2003 ,NTLA -3001 ,andNTLA -6001 programs, inanyfuture

studies, including human clinical trials ;theability tooptimize theimpact ofourcollaborations onourdevelopment programs, including, butnotlimited to,ourcollaboration with

Regeneron Pharmaceuticals, Inc.(“Regeneron”), including ourco-development programs forhemophilia Aandhemophilia B,with AvenCell Therapeutics, Inc.(“AvenCell ”)for

thedevelopment ofuniversal CAR- Tcelltherapies, with SparingVision SAS (“SparingVision ”)forthedevelopment ofophthalmic therapies, with Kyverna Therapeutics, Inc.